Ensysce Biosciences (ENSC) Competitors $2.10 -0.04 (-1.64%) As of 01:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENSC vs. SXTC, OVID, NAII, SLGL, BIVI, CGTX, CMMB, ASBP, LGVN, and ELEVShould you be buying Ensysce Biosciences stock or one of its competitors? The main competitors of Ensysce Biosciences include China SXT Pharmaceuticals (SXTC), Ovid Therapeutics (OVID), Natural Alternatives International (NAII), Sol-Gel Technologies (SLGL), BioVie (BIVI), Cognition Therapeutics (CGTX), Chemomab Therapeutics (CMMB), Aspire Biopharma (ASBP), Longeveron (LGVN), and Elevation Oncology (ELEV). These companies are all part of the "pharmaceutical products" industry. Ensysce Biosciences vs. Its Competitors China SXT Pharmaceuticals Ovid Therapeutics Natural Alternatives International Sol-Gel Technologies BioVie Cognition Therapeutics Chemomab Therapeutics Aspire Biopharma Longeveron Elevation Oncology China SXT Pharmaceuticals (NASDAQ:SXTC) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment, valuation and community ranking. Does the media favor SXTC or ENSC? In the previous week, Ensysce Biosciences had 1 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 3 mentions for Ensysce Biosciences and 2 mentions for China SXT Pharmaceuticals. Ensysce Biosciences' average media sentiment score of 0.72 beat China SXT Pharmaceuticals' score of 0.43 indicating that Ensysce Biosciences is being referred to more favorably in the news media. Company Overall Sentiment China SXT Pharmaceuticals Neutral Ensysce Biosciences Positive Do institutionals & insiders have more ownership in SXTC or ENSC? 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Comparatively, 7.9% of Ensysce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, SXTC or ENSC? China SXT Pharmaceuticals has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Is SXTC or ENSC more profitable? China SXT Pharmaceuticals has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -179.26%. China SXT Pharmaceuticals' return on equity of 0.00% beat Ensysce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets China SXT PharmaceuticalsN/A N/A N/A Ensysce Biosciences -179.26%-292.81%-158.83% Which has preferable earnings and valuation, SXTC or ENSC? China SXT Pharmaceuticals has higher earnings, but lower revenue than Ensysce Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChina SXT Pharmaceuticals$1.82M16.84-$3.10MN/AN/AEnsysce Biosciences$2.23M2.24-$10.61M-$6.54-0.32 Does the MarketBeat Community believe in SXTC or ENSC? China SXT Pharmaceuticals received 79 more outperform votes than Ensysce Biosciences when rated by MarketBeat users. Likewise, 61.65% of users gave China SXT Pharmaceuticals an outperform vote while only 50.00% of users gave Ensysce Biosciences an outperform vote. CompanyUnderperformOutperformChina SXT PharmaceuticalsOutperform Votes8261.65% Underperform Votes5138.35% Ensysce BiosciencesOutperform Votes350.00% Underperform Votes350.00% SummaryChina SXT Pharmaceuticals beats Ensysce Biosciences on 8 of the 13 factors compared between the two stocks. Get Ensysce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ENSC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENSC vs. The Competition Export to ExcelMetricEnsysce BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.98M$6.92B$5.61B$8.57BDividend YieldN/A2.54%5.28%4.17%P/E Ratio-0.088.6327.2219.81Price / Sales2.24265.57411.31154.51Price / CashN/A65.8538.3234.64Price / Book-0.686.587.014.65Net Income-$10.61M$143.75M$3.23B$248.05M7 Day Performance-11.55%1.52%-0.06%-0.15%1 Month Performance1.69%12.43%8.75%4.50%1 Year Performance-73.52%3.67%32.44%13.76% Ensysce Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENSCEnsysce Biosciences0.3712 of 5 stars$2.11-1.6%N/A-73.4%$4.98M$2.23M-0.0810Short Interest ↓SXTCChina SXT Pharmaceuticals0.3841 of 5 stars$1.32-5.0%N/A-77.4%$20.89M$1.82M0.0090Short Interest ↑Gap DownOVIDOvid Therapeutics4.4015 of 5 stars$0.29+6.5%$2.78+860.1%-91.0%$20.62M$548K-0.6260NAIINatural Alternatives International0.7706 of 5 stars$3.31-0.4%N/A-47.7%$20.43M$125.48M-2.56290News CoveragePositive NewsShort Interest ↑SLGLSol-Gel Technologies3.0315 of 5 stars$7.32+1.5%$40.00+446.7%-11.5%$20.38M$12.10M-21.5250Positive NewsShort Interest ↓BIVIBioVie2.472 of 5 stars$1.07+2.9%$3.00+180.4%+142.1%$19.86MN/A-0.1110CGTXCognition Therapeutics3.6809 of 5 stars$0.32+32.6%$5.63+1,674.4%-87.1%$19.65MN/A-0.3320Short Interest ↓Gap UpHigh Trading VolumeCMMBChemomab Therapeutics3.6083 of 5 stars$1.35+2.3%$8.50+529.6%+11.4%$19.39MN/A-1.3520Positive NewsASBPAspire BiopharmaN/A$0.39-10.5%N/AN/A$19.07MN/A0.00N/ANews CoverageGap DownLGVNLongeveron3.5307 of 5 stars$1.25+0.8%$8.67+593.3%-27.1%$18.66M$2.23M-0.2020Gap DownELEVElevation Oncology3.4045 of 5 stars$0.31+3.7%$3.39+987.6%-88.7%$18.44MN/A-0.3840Trending NewsAnalyst ForecastShort Interest ↓Analyst Revision Related Companies and Tools Related Companies SXTC Alternatives OVID Alternatives NAII Alternatives SLGL Alternatives BIVI Alternatives CGTX Alternatives CMMB Alternatives ASBP Alternatives LGVN Alternatives ELEV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENSC) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ensysce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ensysce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
